"The US Food and Drug Administration (FDA) has granted expedited approval to a supplemental new drug application (sNDA) of Gilead Sciences’ Veklury (remdesivir) to treat adult and adolescent Covid-19 patients in the non-hospital setting.
"The treatment is indicated for people who are at increased risk of progression to severe disease, including hospital admission or death. "
Remdesivir: now bringing poison and death to you in your own home. - Britt
https://www.pharmaceutical-technology.com/news/gilead-veklury-fda-approval-covid-19-outpatients/
No comments:
Post a Comment